How to Win at Angry Birds
Next Lesson →
Lesson 01 - Pharmaceutical Breakthroughs
Transcript
humanOS presents how to win at Angry Birds, the ancestral paradigm for therapeutic revolution. This course was created by me, Doctor Josh Turknet. I am a board certified neurologist, clinical researcher, author and current President of Physicians for Ancestral Health. Our reviewer for this course was Doctor Tommy Wood. Doctor Wood is an assistant professor at the University of Washington in the Department of Neonatology, as well as the cofounder of the British Society for Lifestyle Medicine. This presentation began as an attempt to answer 2 important questions. First, why have we failed so miserably? And second, why do we keep repeating the same mistakes over and over again? Why do we continue the same approach in the face of overwhelming evidence that it's not working? It was roughly 20 years ago that I decided to direct my interest in the neurosciences towards a career as a neurologist. One of my major reasons for doing so was because I thought, as did so many others, that we were on the cusp of a revolution in our ability to treat diseases of the nervous system based on the prevailing wisdom. I expected there to be major advances in, if not cures, for, many of the most devastating illnesses that neurologists face. That was the promise. Now let's look at the reality. Here is a timeline of the major pharmacological breakthroughs in the treatment of the most prominent diseases of the nervous system. Along with the year those breakthroughs were made, these are the dates of discovery for a treatment that to this day remains a gold standard. Meaning that it has yet to be replaced by a superior treatment. Our first breakthroughs occur around the turn of the twentieth century with the discovery of aspirin for stroke prevention and phenobarbital for the treatment of generalized epilepsy. Around the mid twentieth, century we add a couple of new treatments for Mya senior Gravis along with the discovery of tegretol for partial epilepsy and levodopa for Parkinson's disease. This is then followed by a drought in pharmacological breakthroughs, or what we might refer to as a therapeutic winter until the discovery of Sumatriptan in 1991 for the treatment of migraines, though there are some who would debate whether, given its drawbacks, it should be considered a net benefit or net harm. The ensuing period from 1991 up to the present day has seen no further pharmacological breakthroughs. You may note the absence in this timeline of some of the other major common diseases of the nervous system, like Alzheimer's, multiple sclerosis, and diabetic neuropathy. Unfortunately, this unsettling trend is not just limited to neurological diseases. If we review the history of pharmacological breakthroughs for the major diseases of other organ systems, we find a similar story.
We begin with the discovery of things like digitalis for heart failure and insulin for diabetes 2, treatments that are still commonly used in the mid twentieth. Century we add the first antipsychotic for schizophrenia, the first antidepressant for depression, the first oral antidiabetic agent and the first drug for the treatment of high blood pressure. And then after 1970 we have another therapeutic winter while many new drugs have come out during this period of time. None of them are significantly more effective than the existing options and thus do not qualify as pharmacological breakthroughs. And again here note the absence of any pharmacological breakthroughs for the treatment of obesity, despite the enormity of the problem and the amount of resources that have been devoted to finding a pharmacological treatment. This means that for the vast majority of major health conditions that impact humans. The ones that have placed our healthcare system on the verge of collapse, we've essentially made no significant pharmacological advances in the past 50 years. This isn't because our existing treatments work so well that they can't be improved upon, but because we haven't been able to find anything better. One reason I decided to direct my interest in neuroscience into a career in neurology was because it was widely believed at the time I graduated medical school that we were on the verge of a therapeutic revolution. I vividly remember, as a fourth year medical student asking a prominent Alzheimer's researcher at my medical school how long he thought it'd be till we had a cure for the disease. After pausing for a moment, he said 10 years. Again, this was in line with the prevailing sentiment at the time. The reality is it is now 20 years later and we've made no progress. Not only do we not have a cure, we don't even have a treatment that is incrementally better than what was available at the time he made this prediction. In fact, as you may have seen in some recent headlines, the picture here is now considered so bleak that many drug companies are pulling out of Alzheimer's Research altogether. So clearly we were off in our estimates. And if we continue with this base, perhaps a more realistic prediction for finding a drug cure for Alzheimer's might be the year 4237 Or maybe never. All of this, of course, comes in the face of incredible progress in the field of neuroscience itself. In our understanding of the brain and the mechanisms of disease, along with a massive investment of resources into the search for new treatments, to say this failure has been surprising and unexpected is a huge understatement. And all of this begs the question, what on Earth is going on?
Outline
Course Introduction
- HumanOS Course: Winning at Angry Birds, a paradigm shift.
- Creator: Dr. Josh Turknet, board-certified neurologist & President of Physicians for Ancestral Health.
- Reviewer: Dr. Tommy Wood, assistant professor & cofounder of British Society for Lifestyle Medicine.
Core Questions
- Primary Concerns:
- Failure in therapeutic advances.
- Repetition of ineffective strategies despite evidence.
Background
- Dr. Turknet's Journey:
- Interest in neurosciences → career in neurology.
- Anticipated revolution in nervous system disease treatment.
Reality Check: Neurological Advances
- Pharmacological Breakthroughs:
- Early 20th century: Aspirin for stroke, Phenobarbital for epilepsy.
- Mid 20th century: Treatments for Myasthenia Gravis, Tegretol for partial epilepsy, Levodopa for Parkinson’s.
- 1991: Sumatriptan for migraines—marked the last major breakthrough.
Therapeutic Winter
- Post-1991 Drought:
- No significant pharmacological breakthroughs across major neurological diseases.
- Similar trends in other major diseases (heart failure, diabetes, psychiatric conditions).
Wider Medical Landscape
- General Medical Advances:
- Early to mid 20th century: Foundational treatments for heart failure, diabetes, schizophrenia, depression, hypertension.
- Post-1970: No significant advances, despite new drugs.
The Problem Magnified
- Healthcare Crisis:
- Last 50 years: No significant pharmacological advancements for major health conditions.
- Healthcare system strain due to ineffective treatments.
Personal Reflection
- Expectation vs. Reality:
- Initial optimism for therapeutic revolution.
- 20 years later: No progress in Alzheimer’s treatment or cure.
Conclusion
- Industry Response:
- Pharmaceutical companies withdrawing from Alzheimer's research.
- Neuroscience Progress:
- Despite advancements in understanding, no new treatments emerged.
- Alarming Prediction:
- Possibility of never finding a cure for Alzheimer’s at current pace.
Quiz Yourself
- Why did Dr. Josh Turknet decide to focus his career on neurology, and how does this relate to the outcomes observed in the course of his career?
- He was interested in the monetary benefits of the field, which aligned with the widespread therapeutic breakthroughs he later observed.
- He believed in the imminent therapeutic revolution in nervous system disease treatment, a belief that was contradicted by the lack of significant advancements.
- He was inspired by the advancements in Alzheimer's research, accurately predicting the rapid development of a cure.
- He had a personal connection to a neurological disease, which led to the discovery of a groundbreaking treatment.
- B
- What was identified as the last major pharmacological breakthrough in the treatment of neurological diseases, and in which year was it discovered?
- Levodopa for Parkinson's disease in the mid-20th century.
- Sumatriptan for the treatment of migraines in 1991.
- Aspirin for stroke prevention at the turn of the 20th century.
- The first antipsychotic for schizophrenia in the mid-20th century.
- B
- What significant trend was highlighted regarding the development of treatments for major diseases since 1991?
- A surge in pharmacological breakthroughs for neurological diseases.
- A therapeutic winter, with no significant pharmacological breakthroughs.
- Major advancements in the treatment of Alzheimer's disease.
- The discovery of numerous effective treatments for obesity.
- B